MARTINSRIED / MUNICH, Germany, Dec. 3, 2013 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced today that the European Patent Office has granted a patent covering the Company’s cancer compound MOR208. The new patent (EP2383297) covers the antibody’s protein and nucleic acid sequences as well as pharmaceutical compositions comprising the same. The new patent has a scheduled expiry date in 2027, not including any potential patent office or regulatory extensions, and is licensed to MorphoSys AG from Xencor, Inc.
Help employers find you! Check out all the jobs and post your resume.
